Collagen is a brand-new triple-helix protein molecule that makes up a crucial part of the extracellular matrix (ECM). The ECM is involved in every stage of wound healing. In the advanced wound care sector, there are a variety of collagen technologies. How do we decide which product to buy?
Collagen technology dressings are designed to inhibit protease activity while transitioning the wound to a healing state. Collagen advanced wound care dressings are showing to be a catalyst in wound chronicity, promoting tissue growth, autolysis, angiogenesis, collagen deposition, and wound re-epithelialization.
MMP regulating dressings, also known as collagen technology dressings, are appropriate for chronic wounds because they address high levels of matrix metalloproteinases (MMPs), which degrade both viable and non-viable collagen. We don’t have a technology that can measure MMP levels in a wound bed right now. What we do know is that MMPs must be present in the appropriate amount, at the right time, and in the right place for a wound to heal properly. Collagen, especially kinds I and II, makes up around 70-80 percent of the ECM of skin.
Collagen can come from any species, but it’s most commonly found in bovine, porcine, equine, piscean, and avian tissues. Collagen acts as a template for future tissue formation in its matrix structure, and the primary structure continues to attract fibroblasts to the region. When the healing process reaches the maturation stage, it is thought to boost the deposition of orientated collagen fibers, which increases the new tissue’s tensile strength.
NON-HYDROLYZED COLLAGEN (retaining original collagen molecule)
Collagen in its “purest form” is non-hydrolyzed collagen. Non-hydrolyzed collagen retains a higher percentage of its native triple helix protein structure, providing for greater molecular and scaffold stability during wound healing. To improve thermal endurance, mechanical strength, and the ability to engage in precise interactions with other biomolecules, collagen must maintain its triple helix form.
When collagen molecules fragment, their triple helix form is lost, the function shifts to a more rejuvenated condition by activating monocytes, resulting in the creation of more macrophages, and so on. Non-Hydrolyzed collagen particles or powders may improve scaffolding and cell migration in forming granulation tissue.
COLLAGEN THAT HAS BEEN HYDROLYZED (fragmented process)
The fundamental disadvantage of hydrolyzed collagen is that it cannot form scaffolds on its own due to the low molecular weight of the peptides, but it can be combined with other copolymers like cellulose and chitosan. It’s called “dead-protein.” This form of collagen is made predominantly from non-bioavailable connective tissue. Because the derived source must undergo hydrolysis and an aggressive chemical procedure, it contains post-collagen amino acids.
Because hydrolyzed collagen is broken down into its component amino acids, glycine, proline, and hydroxyproline, it loses its natural triple helical shape and is no longer in its “purest form.” More active sites in the wound bed are created by hydrolyzed collagen fragments in the form of particles or powder, which support fibronectin binding and fibroblast activity.
Although collagen dressings are not all created equal, the goal is to accelerate wound healing. Wound healing entails a series of steps that must be completed in a logical order. Hemostasis, inflammatory, proliferative, and remodeling are all conditions that can occur in the body. The damaged tissue is spontaneously restored by the body in order for wounds to heal. When the wound does not go through this cascade healing process, the wound becomes chronic or difficult to heal. Chronic inflammation elevates metalloproteases (MMPs), and the formation of biofilm in the wound can all contribute to this. During the healing process, collagen dressings can assist maintain an optimal moist environment, induce the deposition of new collagen fibers, and support new tissue regeneration.
When used in conjunction with wound bed preparation, moist-wound healing, offloading/redistribution, and education, different Collagen technology dressings have been found to advance chronic complex wounds towards the wound healing trajectory. When choosing advanced wound care products, healthcare providers should evaluate quality, product features, pricing, and availability.
The wound assessment and clinical data should be used to choose a collagen dressing. Consider the type and supply of collagen in an advanced wound care collagen dressing, as well as the production method, cost-effectiveness, user-friendliness, and bioactive technology. Bioactive collagen materials help to activate various cells, resulting in a moist wound healing environment that promotes wound healing. Clinical evidence suggests that collagen-based dressings may be capable of influencing wound biochemistry and addressing chronic wound imbalances.
Human BioSciences, Inc. blog offers education and tips; however,the information provided by this website or company is not a substitute for medical treatment or advice.
Mrs. Vann is responsible for branding, design, and public outreach efforts for the company. Mrs. Vann has over five years of experience in the creative design arena. She has spearheaded multiple marketing campaigns, both domestic and international. She also has experience producing several television and live-stage programs. She has a Bachelor’s Degree in Film and Video Studies from George Mason University.
Mr. Patel is the Vice President of Operations for Human BioSciences. As such, he is responsible for strategy development for optimal growth, organizing multiple teams and implementing optimal product delivery for the growth of HBS. He has served multiple positions within HBS since 2001, including Operations Manager. With an MBA in Pharmaceutical Healthcare and a Bachelor’s in Pharmaceuticals, Mr. Patel brings deep technical knowledge in collagen product production with a rich history in managing teams.
As the President of Human BioSciences, Dr. Rohan K Jain is responsible for the company’s overall operations, with a focus on research and development. Dr. Jain has supervised and conducted extensive research in the collagen, biomaterials, and protein space, resulting in the release of numerous new products to the market. Prior to his role at HBS, Dr. Jain was a capital markets attorney at Shearman & Sterling LLP. He received his Doctorate in Law and his MBA from New York University; his Bachelor’s degrees in Biomedical Engineering and Materials Science and his Master’s in Engineering Management from Johns Hopkins University. He is a member of the New York and Maryland bars.
Cheryl Carver, LPN, WCC, CWCA, CWCP, DAPWCA, FACCWS is responsible for clinical education and training initiatives for customer accounts. Ms. Carver has amassed a wealth of clinical knowledge and industry experience in her more than 20 years as a board-certified wound care nurse. She has authored over 200 published white papers, ebooks, blogs, and articles for WoundSource and freelance.
Dr. Goebel is responsible for the company’s physical infrastructure and global expansion efforts through partnerships. Prior to joining HBS, Dr. Goebel was Managing Director at the Graf Matuschka Group in Munich, Germany, where he was actively involved in restructuring and privatization in East Germany and Eastern Europe. He was also a member of the American group of the EBRD European Bank for Reconstruction and Development in the privatization of the Russian economy and military complex. He has over forty years’ experience in many different industries including medical devices, pharmacy, and others. Dr. Goebel earned his Doctorate and Postdoctoral degrees in Economics in East Berlin.
Mr. Kumar is responsible for the company’s overall accounting and finance activities with a focus on internal control and taxation.
Mr. Kumar has over 25 years of public and corporate accounting experience. He is a Certified Public Accountant, licensed in the State of Virginia, Maryland, and Washington D.C., and an Enrolled Agent authorized to practice before the Internal Revenue Service. Mr. Kumar is also a Chartered Accountant and fellow member of the Institute of Chartered Accountants of India. Mr. Kumar received his Master’s degree in Commerce from Himalayan University in India.
Mr. Slovick is responsible for all regulatory and quality affairs in the company. Mr. Slovick has worked in regulatory, quality, and clinical services within the medical device and diagnostics industry for nearly 40 years. He founded Methodize Inc., to offer strategic support for approval of medical devices and in vitro diagnostics products. Mr. Slovick has a Bachelor’s degree in Management Information Systems.
Mr. Agarwal is responsible for Corporate Business Development, Sales, and Product Development, both locally and internationally for the company. Mr. Agarwal has over six years of corporate sales and business development experience. He completed his Master of Science in Engineering Management degree from Johns Hopkins University with a technical concentration in Mechanical Engineering. In the past, he has also worked as a fundraising volunteer for three years and thus gained insights in community fundraising and business development. Additionally, he has interned at a manufacturing firm and understood various intricacies involved in manufacturing ranging from the floor level to the supply chain. He has published a paper on Omni Channel Supply Chain and is a certified Lean Six Sigma associate. He has also interned as a business development consultant to a startup for market research and pricing strategies in Israel. Equipped with a combination of management and technical background acquired from his diverse experiences and education, he is perfectly suited to lead the business development efforts for Human BioSciences.
